Apotea (APOTEA.ST) Stock Analysis & AI Equity Report
Apotea (APOTEA.ST) overview
Apotea (APOTEA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Apotea reported revenue of SEK 7,203m and operating profit of SEK 304m; the year-end share price was 92.22 SEK and market capitalisation was SEK 9,597m. Apotea is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Apotea's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Apotea
Apotea is a Swedish online pharmacy that sells prescription and over-the-counter medicines, health and wellness products, beauty and skincare items, and products for pets. The company provides customer support through pharmacists and related specialists, and its business is built around e-commerce, a broad assortment, and logistics for fast home delivery across Sweden.
Generate the Apotea report
Apotea is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Apotea and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.